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1. Introduction 
Oxindoles are present in many natural and synthetic products 
showing pharmaceutical and biological activities.1,2 Oxindole 
derivatives have been employed as anti-cancer,3 antimicrobial,4,5 
anti-HIV,6 and antimalarials.7,8 In the past we demonstrated the 
utility of oxindoles as peptidomimetics capable of mimicking a 
β-turn structure.9,10 The most common  derivatives are 3,3-
disubstituted oxindoles and 3-spirooxindoles containing a 
quaternary carbon centre and diverse functional groups. 
Spirooxindoles are also related to a series of alkaloids that were 
first isolated from plants of the Apocynaceae11-13 and 
Rubiaceae14-17 families.  
The importance of isatin derivatives and their multiple 
applications has stimulated the interest of the researchers. In the 
last few years, lots of work has been devoted to finding an easy 
way to produce 3-substituted oxindoles, if possible with a 
controlled configuration at the stereocentre. Following our 
research activity in the preparation of oxindole-based 
compounds,18-21 we became interested in the metal-free reduction 
of 3-yliden-oxindole derivatives by means of biocatalysis, in 
order to obtain 3-alkyl-oxindoles as possible substrates for 
further modifications. The use of biocatalysis offers the 
advantage of mild reaction conditions with limited use of organic 
solvents. Conversions are usually very high and when prochiral 
substrates are employed, chiral compounds can be obtained in 
high enantiomeric excesses. baker’s yeast has been demonstrated 
to be an efficient catalyst for the reduction of activated olefins. 
This activity is due to the presence in this yeast of ene reductase 
(ER) enzymes of the OYE family. The use of baker’s yeast for 
chemical transformations is encouraged by the fact that reactions 
are carried out in tap water, at room temperature and in the air in 
simple apparatus. The recovery of the products is easily realized 
by solvent extraction. An improvement of the recovery step is 
possible when the substrates are supported onto insoluble 
polystyrene resin, with the so-called Substrate Feeding Product 
Removal (SFPR) technique. In accordance with our experience in 
the use of biocatalytic systems for the reduction of activated 
olefins,22-26 we decided to investigate the baker’s yeast mediated 
reduction of olefins 1-13. Very recently, a similar approach using 
pseudomonas Monteilii was reported,27 thus confirming the 
urgent interest in this topic.28 Nevertheless, baker’s yeast is more 
simple to handle and scaling up to the preparation of grams of 
product is easily achievable. We selected differently substituted 
olefins in order to explore both the effect of different activating 
groups on the reactivity and the role of steric hindrance. 
2. Results and discussion 
The substrates were synthesized according to Schemes 1 and 
2. Compounds 1-9 were prepared by standard Wittig olefination 
on commercial isatins. 
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Scheme 1. Synthesis of 1-9 by Wittig olefination 
Compounds 10-12 were produced by the reaction of isatin 
with the corresponding arylmethylketone with catalytic DEA 
(diethylamine) followed by dehydration with thionyl chloride. 
The reaction of isatin with ethylcyanoacetate and catalytic DBU 
(1,5-diazabiciclo(5.4.0)undec-5-ene) afforded compound 13, 
while grinding isatin with malononitrile and a substechiometric 
equivalent of water afforded derivative 14. 
 
Scheme 2. Synthesis of compounds 10-14 by condensation 
reactions on isatin. 
The olefins were then submitted to reaction with dried yeast 
(Sigma-Aldrich) in tap water (150 g/L) in the presence of D-
glucose (15.0 g/L). Substrates were added at a concentration of 3 
g/L. Reaction were usually carried on the 100 mg scale of olefin. 
If necessary, some drops of ethanol were added to facilitate the 
dissolution of substrates. The mixtures were incubated at 35 °C 
for 72 h in an orbital shaker. The same conditions were applied 
when using the SFPR technique. In this case the resin (Amberlite 
XAD 1180-N) was loaded in a 1:20 substrate/resin ratio. 
 
Scheme 3. Reaction of olefins 1-14 with baker’s yeast. 
 
Results are reported in Table 1. Products 15-23 were isolated 
from substrates 1-7, 13, 14 after chromatographic purification. 
As expected when unsaturated ketones 8-12 were employed, the 
corresponding saturated alcohols 24-28 were isolated as the 
major product, due to the concomitant activity of the alcohol 
dehydrogenase enzymes (ADH) which are present in the baker’s 
yeast. The saturated ketones 24a-28a were also obtained in a 2-
6% yield, according to 1H NMR analysis of the crude reaction 
mixture (products were not isolated).  
Substrate product Yielda Yieldb drc 
1 15 71% 83% - 
2 16 72% 77% - 
3 17 58% 79% - 
4 18 68% 88% - 
5 19 69% 78% - 
6 20 <5%c <5%c 60:40 
7 21 67% 75% - 
8 24 66% 82% 55:45 
9 25 62% 70% 50:50 
10 26 59% 81% 52:48 
11 27 44% 69% 57:43 
12 28 51% 77% 51:49 
13 22 - - - 
14 23 14%c 13%c - 
     
aReaction performed without the use of resin. bWith resin (SFPR). cCalculated 
from 1H NMR and GC/MS analysis on the crude reaction mixture (product 
not isolated) 
 
All the substrates could be efficiently transformed into 
products by baker’s yeast. As expected, the use of the SFPR 
allowed isolation of the final products in significantly higher 
yields. The lowest yields were obtained with tetra-substituted 
olefins (21-23) probably due as a result of their increased steric 
hindrance. Despite the use of prochiral olefins, disappointingly 
no ee was detected after HPLC analysis of the product 18. The 
preparation of enantioenriched 3-alkyl 2-oxindoles has been 
previously reported in the literature by means of different 
approaches.29-33 In particular the reduction of 3-yliden-oxindoles 
catalysed by a chiral iridium complex was reported to proceed 
with ee up to 93%.34 We reasoned that our results might be 
ascribable to an epimerisation of the newly formed stereogenic 
centre.35 The chromatogram of the chiral HPLC separation of 
compound 18 is reported in Figure 1. The presence of a plateau 
between the peaks of the two enantiomers is characteristic of a 
racemization process of the product during the column elution,36 
due to epimerisation at the C3 position. To further investigate 
this aspect, the 1H NMR spectrum of 18 was first recorded in 
CDCl3. Upon addition of few drops of CD3OD, after 24 h at room 
temperature we observed the complete disappearance of the C3 
proton as a consequence of its exchange with deuterium (see 
Figure 1). These experiments proved the configurational lability 
of the C3 stereocenter due to the acidity of the hydrogen at C3. 
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image) and 1H-NMR deuteration experiments are reported. 
Alcohols 25-28 were obtained as a 1:1 mixture of 
diastereoisomers. In this case, as expected, the reduction of the 
carbonyl group by ADH enzymes proved to be very 
enantioselective, whereas the epimerization at C3 led to no 
diastereoisomeric excess. In fact, for representative compounds 
24 and 25 an enantiomeric excess up to 98% could be measured 
by chiral HPLC. We did not determine the absolute configuration 
at the alcohol stereocenter of the major enantiomer, however, 
according to the Prelog’s rule37, we could suggest the 
stereochemical outcome proposed in Scheme 4. For compound 8, 
bearing the small methyl group, the S configuration can be safely 
assigned. Whereas in the presence of an aryl substituent, the 
opposite result should be expected. 
 
Scheme 4. Possible stereochemical outcome of the ADH-
mediated reduction, according to the Prelog’s rule. 
According to the activation model for the reduction of 
activated olefins by baker’s yeast, as observed for substrates 6, 
13 and 14, the reaction suffers from the steric hindrance around 
the carbon-carbon double bond. Despite the high steric demand 
introduced by the oxindole moiety, for trisubstituted olefins the 
conversions were good in all cases. Moreover, with the exception 
of compounds 1-3, two different activating EWGs are present on 
the double bond, thus enabling different possible interaction 
modes with the ene-reductase enzymes. To better understand 
these aspects of the substrate-enzyme interaction, we performed a 
study on the docking modes of the oxindole-based olefins in an 
OYE 2 model receptor. Though in baker’s yeast different ene-
reductase enzymes are present, the activation of substrates and 
hydride transfer from FMNH occur in similar way.38,39 Moreover, 
according to our experience, the stereochemical outcome of the 
reduction by baker yeast or isolate enzymes is in  most cases the 
same. 
24
  The homology model of the OYE 2 enzyme was created 
with the YASARA software and docking experiments were 
carried out with Autodock 4.2. According to the mechanism, in 
our model the substrate is activated by interaction of the EWG of 
the olefin with His192 and Asp195 through hydrogen bonds. The 
olefin is then reduced by 1,4-addition of hydride from FMNH, 
followed by protonation from Tyr197 (Figure 2). 
 
Figure 2. Activation mode for the OYE reduction of olefins. 
We investigated the binding modes for representative 
compounds 1, 4, 8, and 14. The lowest energy poses for 
methylester 4 and olefin 1 are reported in Figure 3. For 4 a 
normal mode of activation is realized, with the coordination of 
the carboxymethyl group to the active site. A further stabilizing 
hydrogen bond interaction between the oxindole nitrogen and 
Tyr376 is detected. A similar situation is present for compound 8 
(see SI). In compound 1 the activation is still possible through the 
interaction with the oxindole carbonyl group, but with a different 
arrangement of the double bond, similar to the “flipped” mode 
previously reported with other substrates. This result is 
noteworthy, since the oxindole ring forces an s-cis conformation 
for the carbonyl-olefin system, a quite uncommon geometry for 
the OYE reduction of olefins. On the contrary, the docking pose 
obtained for 14 revealed a poor interaction of the substrate. In 
fact, only one of the two cyano residues can form a hydrogen 
bond and only with His192 (see SI). This result could be an 
explanation of the poor reactivity of this substrate. 
 
Figure 3. Comparison of the binding modes of 4 (left) and 1 (right) in the 
active site of OYE2. Reducing cofactor FMNH is depicted in yellow. 
3. Conclusions 
In this work we demonstrated the utility of baker’s yeast for 
the reduction of 3-ylidene oxindoles, aimed at the preparation of 
3-substituted oxindoles. Good results were obtained even with 
highly hindered tri-substituted olefins bearing different functional 
groups. No enantioselection was achieved, due to the easy 
racemization of the reduced product in the reaction medium. 
When a keto group was present on the double bond, the 
diastereoisomeric saturated alcohols were obtained with very 
high enantiomeric  excess.  
 
4. Experimental Section 
4.1. General 
All solvents were distilled and dried over sodium or calcium 
chloride, when necessary, prior to use. All chemicals were 
purchased from commercial sources and used directly, unless 
indicated otherwise. All reactions were monitored by thin layer 
chromatography (TLC) on precoated silica gel 60 F254; spots 
were visualized with UV light (254 nm) or by treatment with 1% 
aqueous KMnO4 solution. Products were purified by flash 
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chromatography on silica gel 60 (230 - 400 mesh). GC–MS 
analyses were performed by using an HP-5 MS column (30 m × 
0.25 mm × 0.25 µm, Agilent). The following temperature 
program was employed: 60 °C (1 min)/6 °C min−1/150 °C (1 
min)/12 °C min−1/280 °C (5 min). The enantiomeric excess was 
determined by HPLC on a Chiralpak AD column (eluent 9:1, 
hexane : isopropanol, flow rate 0,75 mL/min). NMR spectra were 
recorded with a Bruker Avance 400 MHz spectrometer. Chemical 
shifts (δ) are expressed in ppm relative to TMS at δ = 0 ppm for 
1H NMR and relative to CDCl3 at δ = 77.16 ppm for 13C NMR. 
Some 13C NMR spectra have been recorded using the APT pulse 
sequence; the signals of CH and CH3 are positive while CH2 and 
quarternary carbons are negative. FT-IR spectra were recorded in 
the ATR mode on an Agilent instrument. HR-EI mass spectra 
were measured on VG 70–70 EQ–HF instrument equipped with 
its standard sources. 
4.2. General procedure for the synthesis of compounds 1-3 by 
Wittig olefination. 
To a solution of the phosphonium salt (10.0 mmol) in THF 
(70 mL) at 0°C, t-BuOK (1.26 g, 11.22 mmol) was added. The 
reaction was stirred for 1 h to allow the formation of the ylide. A 
solution of isatin (10.0 mmol) in THF (70 mL) was added slowly 
to the reaction mixture at 0°C. The resulting solution was stirred 
for 15 h at rt. The reaction was poured into saturated ammonium 
chloride (70 mL) at 0° C. The compound was extracted with 
DCM (3 x 100 mL). The combined organic layers were dried 
(Na2SO4) and the solvent was removed under reduced pressure. 
The crude product was purified by silica gel column 
chromatography eluting with 2:8 EtOAc/hexane. 
4.3. General procedure for the synthesis of compounds 4-9 by 
Wittig olefination. 
To a solution of isatin (0.04 mol) in DCM (150 mL), the 
corresponding previously prepared stabilized ylide (0.04 mol) 
was added. The mixture was stirred for 24 h at rt. The solution 
was concentrated under reduced pressure and the residue purified 
by silica gel column chromatography eluting with 2:8 
EtOAc/hexane. to provide the product as a solid. 
4.4. General procedure for the synthesis of compounds 10-12 
Isatin (6 mmol) and the methylketone (6 mmol) were 
dissolved in 20 mL of ethanol. Diethylamine (124 µL, 1.2 mmol) 
was added and the reaction mixture was stirred at rt for 48 h. The 
solvent was removed under reduced pressure and the residue was 
dissolved in 15 mL of DCM and SOCl2 (290 µL, 4 mmol) was 
added. After 2 h at rt the solvent was removed under reduced 
pressure and the crude product was recrystallized from ethanol to 
afford the pure compound. 
Compounds 1340 and 1441 were prepared according to 
literature.  Spectroscopic data for compounds 1,42 2,43 3,44 4,45 5,46 
8,47 9,48 were in agreement with literature values. 
 
4.5. Spectroscopic data for compounds 1-14: 
4 .5 .1 .  3-methy leneindol in -2 -one1 
1H NMR (400 MHz, CDCl3) δ 7.56 (s, 1H), 7.48 (d, 
J = 7.3 Hz, 1H), 7.25 (d, J = 7.7 Hz, 1H), 7.01 (d, J = 7.7 Hz, 
1H), 6.86 (d, J = 7.6 Hz, 1H), 6.39 (s, 1H), 6.12 (s, 1H). 13C 
NMR (101 MHz, CDCl3) δ 178.0, 142.3, 134.9, 127.7, 125.4, 
124.6, 122.4, 120.1, 110.3. 
4.5 .2 .  3-ethyl idene indol in -2-one2 
1H NM  (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 7.48 (d, J = 
7.5 Hz, 1H), 7.41 (t, J = 7.5, 1H), 7.09 (q, J = 6.4 Hz, 1H), 6.93 
(t, J = 7.4, 1H), 6.79 (d, J = 7.5 Hz, 1H),  2.32 (d, J = 6.4 Hz, 
3H). 13C NMR (101 MHz, DMSO-d6) δ 168.3, 140.2, 137.0, 
128.3, 127.7, 123.3, 120.8, 119.3, 109.3, 13.7 
4.5 .3 .  3-benzyl ideneindol in-2 -one3 
1H NMR (400 MHz, CDCl3)  δ 8.29-8.25 (m, 2H), 7.78 (s, 
1H), 7.57-7.51 (m, 2H), 7.48-7.42(m, 3H), 7.22 (t, 1H, J = 8.0 
Hz), 7.04 (d, 1H, J = 7.6 Hz), 6.84 (t, 1H, J = 8.0 Hz). 13C NMR 
(101 MHz, CDCl3) δ 167.5, 139.5, 137.6, 133.7, 132.0, 130.6, 
128.9, 128.3, 126.1, 125.3, 121.8, 119.3, 109.4. 
4.5 .4 .  methyl -2- (2 -oxoindol in-3 -y l idene)ace ta te4  
1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H) , 8.53 (s, 1H), 7.28-
7.36 (m, 1H), 7.00-7.09 (m, 1H), 6.84-6.88 (m, 2H), 3.8 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.1, 165.9, 150.8, 132.6, 130.5, 
129.2, 122.9, 122.0, 110.0, 52.1. 
4.5 .5 .  2-(2 -oxo indol in -3-yl idene)aceton i tr i le5  
1H NMR (400 MHz, DMSO-d6) δ 10.89 (s, 1H), 7.86 (d, J = 
7.6 Hz, 1H), 7.42 (dd, J = 7.6, 7.6 Hz, 1H), 7.10 (dd, J = 7.6, 7.6 
Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.53 (s, 1H). 13C NMR (101 
MHz, DMSO-d6) δ 166.9, 145.6, 144.7, 134.8, 124.9, 123.3, 
120.3, 117.8, 111.9, 98.6. 
4.5 .6 .  Ethy l  (Z)-2 - (2-oxoindol in -3-
yl idene)propanoate  6 .  
Yellow solid. m.p. 180°C 1H NMR (400 MHz, CDCl3) δ 8.74 
(s, 1H), 7.58 – 7.44 (m, 1H), 7.24 (t, J = 7.8 Hz, 1H), 7.02 (td, J 
= 7.7, 1.1 Hz, 1H), 6.85 (dt, J = 7.7, 0.8 Hz, 1H), 4.40 (q, J = 7.2 
Hz, 2H), 2.43 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 170.0, 169.3, 141.0, 140.4, 129.8, 125.2, 122.9, 
122.0, 121.1, 110.0, 61.8, 16.4, 14.1. νmax(ATR) 3079, 1726, 
1703, 1613, 1467, 1113. HRMS (EI): calculated for C13H13NO3: 
231.0895; found 231.0894. 
4.5 .7 .  Methy l  (Z)-2 - (5-methoxy-2-oxoindol in-3 -
yl idene)ace ta te  7  
Brown solid. m.p. 184°C  1H NMR (400 MHz, CD3CN) δ 8.37 
(s, 1H), 8.10 (d, J = 2.7 Hz, 1H), 6.94 (dd, J = 8.5, 2.7 Hz, 1H), 
6.81 (d, J = 8.5 Hz, 1H), 6.68 (s, 1H), 3.84 (s, 3H), 3.78 (s, 3H). 
13C NMR (101 MHz, CD3CN) δ 178.4, 172.1, 156.1, 136.4, 
131.1, 113.1, 111.7, 110.2, 52.0, 42.9, 34.4, 14.2. νmax(ATR) 
3175, 2922, 1702, 1437, 1207. HRMS (EI): calculated for 
C12H11NO4: 233.0688; found 233.0692. 
4.5 .8 .  (Z)-3 - (2-oxopropyl idene) indol in-2 -one8  
1H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 7.8 Hz, 1H), 7.84 
(s, 1H), 7.32 (td, J = 7.7, 1.3 Hz, 1H), 7.27 – 7.22 (m, 1H), 7.09 – 
6.95 (m, 1H), 6.82 (d, J = 7.8 Hz, 1H), 2.47 (d, J = 1.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 198.55, 169.95, 155.76, 143.50, 
135.63, 128.63, 127.87, 123.09, 120.75, 133.17, 32.35. 
4.5 .9 .  (Z)-3 - (2-oxo-2 -phenylethyl idene)indol in -2 -
one9 
1H NMR (400 MHz, CDCl3) δ 8.34 (dt, J = 7.8, 0.6 Hz, 1H), 
8.18 – 8.05 (m, 2H), 7.89 (s, 1H), 7.71 – 7.63 (m, 1H), 7.59 – 
7.50 (m, 2H), 7.36 – 7.30 (m, 1H), 7.04 (td, J = 7.7, 1.0 Hz, 
1H), 6.87 (dd, J = 7.8, 1.1 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 191.1, 169.4, 143.3, 137.6, 136.7, 133.8, 132.7, 
128.9, 128.8, 128.0, 126.5, 122.9, 120.7, 110.1. 
4.5 .10 .  (Z)-3 - (2- (4 -chlorophenyl )-2 -
oxoethyl idene)indol in -2 -one 10 .  
Red solid. m.p. 225°C  1H NMR (400 MHz, DMSO-d6) δ 
10.79 (s, 1H), 8.09 (d, J = 8.6 Hz, 2H), 8.07 – 8.03 (m, 1H), 7.69 
(s, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.36 (td, J = 7.7, 1.3 Hz, 1H), 
6.97 (td, J = 7.7, 1.1 Hz, 1H), 6.89 (dt, J = 7.8, 0.8 Hz, 1H). 13C 
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136.2, 133.6, 131.0, 129.7, 127.3, 125.8, 122.2, 120.4, 110.9. 
νmax(ATR) 3146, 3085, 1715, 1495, 1327. HRMS (EI): calculated 
for C16H10ClNO2: 283.0400; found 283.0404. 
4.5 .11 .  (Z)-3 - (2- (4 -methoxyphenyl )-2 -
oxoethyl idene)indol in -2 -one 11 .  
Brown solid. m.p. 197°C  1H NMR (400 MHz, DMSO-d6) δ 
10.76 (s, 1H), 8.06 (d, J = 8.9 Hz, 2H), 7.94 (d, J = 7.7 Hz, 1H), 
7.69 (s, 1H), 7.33 (td, J = 7.7, 1.3 Hz, 1H), 7.13 (d, J = 8.9 Hz, 
2H), 6.94 (td, J = 7.7, 1.3 Hz, 1H), 6.88 (dt, J = 7.8, 0.8 Hz, 1H), 
3.88 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 190.2, 168.7, 
164.4, 145.1, 136.0, 133.0, 131.6, 130.4, 127.1, 127.0, 122.1, 
120.5, 114.9, 110.8, 56.2. νmax(ATR) 3147, 1706, 1603, 1457, 
1010. HRMS (EI): calculated for C17H13NO3: 279.0895; found 
279.0893. 
4.5 .12 .  (Z)-3 - (2- ( furan-2 -yl ) -2-
oxoethyl idene)indol in -2 -one 12 .  
Red solid. m.p. 188°C  1H NMR (400 MHz, DMSO-d6) δ 
10.80 (s, 1H), 8.48 (d, J = 7.8 Hz, 1H), 8.14 (d, J = 1.0 Hz, 1H), 
7.71 (dd, J = 3.7, 1.0 Hz, 1H), 7.59 (s, 1H), 7.39 (td, J = 7.7, 1.0 
Hz, 1H), 7.03 (dd, J = 7.6, 1.1 Hz, 1H), 6.89 (d, J = 8.1 Hz, 1H), 
6.83 (dd, J = 3.7, 1.7 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 
177.2, 168.7, 153.8, 149.6, 145.8, 133.2, 128.6, 128.0, 126.0, 
124.2, 122.3, 120.6, 113.9, 110.8. νmax(ATR) 3186, 2921, 1706, 
1458, 1328. HRMS (EI): calculated for C14H9NO3: 239.0582; 
found 239.0581. 
4.5 .13 .  ethy l-2 -cyano-2 - (2-oxoindol in-3 -
yl idene)ace ta te  13  
1H NMR (400 MHz, CDCl3)  δ 7.94 (d, J = 8.0 Hz, 1H), 7.56 
(s, 1H), 7.13 (t, J = 7.7 Hz, 1H), 6.71 (t, J = 7.8 Hz, 1H), 6.61 (d, 
J = 8.3 Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 1.19 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 165.2, 164.5, 163.8, 135.9, 
127.9, 126.8, 126.4, 124.0, 120.3, 117.2, 106.3, 59.1, 13.7. 
4.5 .14 .  2-(2 -oxo indol in -3-yl idene)malononi tr i l e14 
1H NMR (400 MHz, DMSO-d6) δ 11.21 (s, 1H), 7.89 (d, J = 
8.0 Hz, 1H), 7.57 (dd, J = 8.0, 7.6 Hz, 1H), 7.14 (dd, J = 8.0, 7.6 
Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H). 13C NMR (101 MHz, DMSO-
d6) δ 164.7, 151.5, 147.4, 138.7, 126.7, 123.8, 119.6, 114.0, 
112.5, 112.4, 81.5. 
4.6. General procedure for the baker’s yeast reduction of olefins 
To a mixture of commercial fresh or freeze-dried baker’s yeast 
(Sigma) (7.5 g) in tap water (50 mL) at 40°C, D-glucose (0.75g, 
4.17 mmol) was added. The substrate (100 mg) was added and 
the flask was placed for 2 d in a termo-shaker. The mixture was 
then filtered on a celite pad and washed twice with water (50 mL) 
and once with EtOAc (50 mL). The aqueous was extracted with 
EtOAc (3 × 50 mL). The combined organic layers were dried 
(Na2SO4) and the solvent was removed under reduced pressure. 
The crude residue was purified by silica gel column 
chromatography eluting with 4:6 EtOAc/hexane to give the 
product. 
4.7. Spectroscopic data for compounds 15-17,48 and 18, 1949 
were in agreement with literature values.  
4 .7 .1 .  3-methy l indol in -2 -one 15  
1H NMR (400 MHz, CDCl3) δ 9.23 (1H, br s), 7.21 (2H, td, J 
= 7.4, 0.8 Hz), 7.03 (1H, td, J = 7.5, 1.0 Hz), 6.93 (1H, d, J = 7.5 
Hz), 3.47 (1H, q, J = 7.7 Hz), 1.51 (3H, d, J = 7.7 Hz). 13C NMR 
(101 MHz, CDCl3) δ 181.4, 141.2, 131.2, 127.9, 123.8, 122.3, 
109.7, 41.0, 15.2. 
4.7 .2 .  3-ethyl indo l in -2-one  16 
1H NMR (400 MHz, CDCl3) δ 8.16 (br s, 1H), 7.23 (d, 1H, J = 
7.7 Hz), 7.22 (t, 1H, J = 7.7 Hz), 7.04 (t, 1H, J = 7.7 Hz), 6.88 
(1H, d, J = 7.7 Hz), 3.46 (1H, t, J = 5.8 Hz), 2.04 (m, 2H), 0.93 
(t, 3H, J = 7.5 Hz). 13C NMR (101 MHz, CDCl3) δ 180.1, 141.6, 
129.5, 127.8, 124.1, 122.2, 109.5, 47.0, 23.5, 9.9 
4.7 .3 .  3-benzyl indol in-2 -one 17  
1H NMR (400 MHz, CDCl3) δ 9.32 (1H, br s), 7.29‐7.15 (6H, 
m), 7.03 (1H, td, J = 7.5, 1.0 Hz), 6.92‐6.86 (2H, m); 6.75 (1H, d, 
J = 7.4 Hz), 3.77 (1H, dd, J = 9.3, 4.5 Hz), 3.52 (1H, dd, J = 
13.7, 4.6 Hz), 2.95 (1H, dd, J = 13.7, 9.3 Hz); 13C NMR (101 
MHz, CDCl3) δ 180.1, 141.5, 137.8, 129.4, 129.0, 128.3, 127.9, 
126.6, 124.7, 121.9, 109.8, 47.6, 36.6. 
4.7 .4 .  methyl  2 -(2 -oxoindol in -3 -y l )aceta te  18  
1H NMR (400 MHz, CDCl3) δ 8.88 (br s, 1H), 7.24-7.20 (m, 
2H), 7.01 (d, J = 7.6 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 3.82 (dd, 
J = 4.8, 8.0 Hz, 1H), 3.70 (s, 3H), 3.09 (dd, J = 4.4, 16.8 Hz, 1H), 
2.84 (dd, J = 8.0, 16.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
179.2, 171.6, 141.5, 128.6, 128.3, 124.1, 122.5, 109.9, 52.1, 42.3, 
34.5 
4.7 .5 .  2-(2 -oxo indol in -3-yl )acetoni tr i l e  19  
1H NMR (400 MHz, DMSO-d6) δ 10.62 (1H, s,), 7.39 (1H, d, 
J=7.4 Hz), 7.24 (1H, t, J=7.7 Hz), 7.01 (1H, t, J=7.5 Hz), 6.88 
(1H, d, J=7.7 Hz), 3.82 (1H, t, J=5.9 Hz), 3.20 (1H, dd, J=17.2, 
5.8 Hz), 3.06 (1H, dd, J=17.2, 5.9 Hz). 13C NMR (101 MHz, 
DMSO-d6) δ 176.4, 142.8, 128.6, 127.1, 124.2, 121.6, 118.2, 
109.6, 41.3, 17.6. 
4.7 .6 .  methyl  2 -(5 -methoxy-2 -oxoindol in-3 -
yl )ace ta te  21   
Orange solid. m.p. decompose. 1H NMR (400 MHz, CD3CN) 
δ 8.31 (s, 1H), 6.90 – 6.70 (m, 3H), 3.76 (s, 3H), 3.70 – 3.65 (m, 
1H), 3.64 (s, 3H), 3.00 (dd, J = 16.8, 5.3 Hz, 1H), 2.86 (dd, J = 
17.0, 6.9 Hz, 1H). 13C NMR (101 MHz, CD3CN) δ 171.5, 166.6, 
155.9, 139.4, 138.9, 123.1, 121.7, 119.2, 114.6, 111.3, 56.0, 52.5. 
νmax(ATR) 3263, 2924, 1711, 1487, 1203. HRMS (EI): calculated 
for C12H13NO4: 235.0845; found 235.0841. 
4.7 .7 .  3-(2 -hydroxypropyl ) indol in-2 -one 24 .  mix ture 
o f  two d ias tereoisomers .  
Yellow solid. m.p. 84°C (decompose)  1H NMR (400 MHz, 
CDCl3) δ 9.01 (s, 0.5H, diast A), 8.80 (s, 0.5H, diast B), 7.25 – 
7.13 (m, 2H), 7.09 – 6.98 (m, 1H), 6.93 – 6.84 (m, 1H), 4.24 (td, 
J = 6.4, 3.0 Hz, 0.5H, diast A), 4.17 – 4.08 (m, 0.5H, diast B), 
3.73 – 3.60 (m, 1H), 2.89 (d, J = 6.3 Hz, 1H), 2.16 (ddd, J = 14.0, 
9.1, 4.7 Hz, 0.5H, diast A), 2.04 – 1.82 (m, 1.5H), 1.30 (d, J = 6.2 
Hz, 1.5H, diast A), 1.27 (d, J = 6.3 Hz, 1.5H, diast B). 13C NMR 
(101 MHz, Chloroform-d) δ 181.7 and 181.6, 141.3 and 141.1, 
129.4 and 129.3, 127.1 and 126.8, 123.9 and 123.8, 122.7 and 
122.5, 110.1 and 109.9, 64.4 and 64.2, 44.7 and 44.2, 41.1 and 
40.0, 23.6 and 23.3. νmax(ATR) 3437, 2925, 2987, 1470, 1137. 
HRMS (EI): calculated for C11H13NO2: 191.0946; found 
191.0944. 
4.7 .8 .  3-(2 -hydroxy-2 -pheny lethyl ) indol in -2-one 25 .   
Yellow solid. m.p. 104°C  mixture of two diastereoisomers. 
1H NMR (400 MHz, CDCl3) δ 9.03 (s, 0.5H, diast A), 8.90 (s, 
0.5H, diast B), 7.38 – 6.98 (m, 8H), 6.91 – 6.80 (m, 1H), 5.12 – 
5.03 (m, 1H), 4.74 (s, 0.5H, diast A), 4.17 (s, 0.5H, diast B), 3.69 
(t, J = 7.0 Hz, 0.5H, diast A), 3.59 (dd, J = 9.3, 3.9 Hz, 0.5H, 
diast B), 2.40 (ddd, J = 14.6, 8.1, 4.0 Hz, 0.5H, diast A), 2.27 – 
2.10 (m, 1.5H). 13C NMR (101 MHz, CDCl3) δ 181.7 and 181.6, 
142.8 and 142.6, 141.3 and 141.1, 133.2 and 133.0, 129.4 and 
129.3, 128.8 - 128.6 (2C), 128.3 and 128.1, 127.3 and 127.0 
(2C), 124.0 and 123.8, 122.9 and 122.7, 110.2 and 110.1, 72.8 
and 70.5, 45.3 and 43.0, 40.3 and 39.0. νmax(ATR) 3250, 1698, 
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1620, 1470. HRMS (EI): calculated for C16H15NO2: 253.1103; 
found 253.1106. 
4.7 .9 .  3-(2 - (4-chlorophenyl )-2 -
hydroxyethyl ) indol in -2 -one 26 .  
 Yellow solid. m.p. 125°C  mixture of two diastereoisomers. 
1H NMR (400 MHz, CDCl3) δ 9.03 (s, 0.5H, diast A), 8.90 (s, 
0.5H, diast B), 7.36 – 7.25 (m, 4H, diast A+ diast B), 7.22 – 7.10 
(m, 2H, diast A+ diast B), 7.06 – 6.96 (m, 1H, diast A+ diast B), 
6.90 – 6.83 (m, 1H, diast A+ diast B), 5.15 – 5.01 (m, J = 7.8, 5.4 
Hz, 1H, diast A+ diast B), 4.74 (s, 0.5H, diast A), 4.17 (s, 0.5H, 
diast B), 3.69 (t, J = 6.9 Hz, 0.5H, diast A), 3.59 (dd, J = 9.3, 3.9 
Hz, 0.5H, diast B), 2.40 (ddd, J = 14.6, 8.1, 4.0 Hz, 0.5H, diast 
A), 2.26 – 2.10 (m, 1.5H, diast A+ diast B). 13C NMR (101 MHz, 
CDCl3) δ 181.7 and 181.6, 142.8 and 142.6, 141.3 and 141.1, 
133.2 and 133.0, 129.4 and 129.3, 128.6 and 128.6 (2C), 128.3 
and  128.1, 127.3 and 127.0 (2C), 124.0 and 123.8, 122.9 and 
122.7, 110.2 and 110.1, 72.8 and 70.5, 45.3 and 43.0, 40.3 and 
39.0. νmax(ATR) 3195, 1687, 1613, 1510, 1469, 1247. HRMS 
(EI): calculated for C16H14ClNO2: 287.0713; found 287.0715. 
4.7 .10 .  3-(2 -hydroxy-2 -(4 -
methoxyphenyl )e thyl ) indo l in-2 -one 27 .  
Yellow solid. m.p. 115°C  mixture of two diastereoisomers. 
1H NMR (400 MHz, CDCl3) δ 9.25 (s, 0.5H, diast A), 9.13 (s, 
0.5H, diast B), 7.26 – 7.19 (m, 2H), 7.15 – 7.10 (m, 1H), 7.09 – 
7.01 (m, 2H), 6.94 – 6.88 (m, 1H), 6.78 (dd, J = 7.5, 5.8 Hz, 2H), 
5.01 – 4.94 (m, 1H), 4.38 (bs, 0.5H, diast A), 3.94 (d, J = 5.8 Hz, 
0.5H, diast B), 3.68 (s, 1.5H, diast A), 3.65 (s, 1.5H, diast B), 
3.61 – 3.55 (m, 0.5H, diast A), 3.52 (dd, J = 8.9, 4.3 Hz, 0.5H, 
diast B), 2.39 – 2.29 (m, 0.5H, diast A), 2.22 – 2.01 (m, 1.5H). 
13C NMR (101 MHz, CDCl3) δ 181.8 and 181.6, 159.1 and 158.9, 
141.6 and 141.4, 136.5 and 136.3, 129.7 and 129.6, 128.1 and 
127.9, 127.2 and 126.9 (2C), 124.1 and 123.8, 122.6 and 122.4, 
113.9 and 113.8 (2C), 110.1 and 110.0, 72.7 and 70.6, 55.3 and 
55.2, 45.1 and 43.1, 40.3 and 39.2. HRMS (EI): calculated for 
C17H17NO3: 283.1208; found 283.1205. 
4.7 .11 .  3-(2 - ( furan-2-yl )-2 -hydroxye thyl ) indol in -2-
one 28 .   
Yellow solid. m.p. 101°C (decompose)  mixture of two 
diastereoisomers.1H NMR (400 MHz, CDCl3) δ 8.71 (s, 0.5H, 
diast A), 8.63 (s, 0.5H, diast B), 7.40 – 7.34 (m, 1H), 7.30 – 7.23 
(m, 1H), 7.24 – 7.17 (m, 1H), 7.05 (ddd, J = 7.7, 6.9, 1.0 Hz, 
1H), 6.90 (t, J = 7.2 Hz, 1H), 6.36 – 6.29 (m, 2H), 5.17 (dd, J = 
8.8, 4.6 Hz, 0.5H, diast A), 5.11 (dd, J = 8.0, 3.8 Hz, 0.5H, diast 
B), 4.23 (s, 0.5H, diast A), 3.93 (s, 0.5H, diast B), 3.74 – 3.68 (m, 
0.5H, diast A), 3.65 (dd, J = 9.5, 4.0 Hz, 0.5H, diast B), 2.62 
(ddd, J = 14.5, 7.9, 4.0 Hz, 0.5H, diast A), 2.45 – 2.26 (m, 1.5H). 
13C NMR (101 MHz, CDCl3) δ 181.3 and 181.1, 156.2 and 156.1, 
142.0 and 141.9, 141.2 and 141.0, 129.3, 128.2 and 128.1, 124.2 
and 123.9, 122.8 and 122.7, 110.3 and 110.2, 110.0 and 109.9, 
106.3 and 106.0, 66.9 and 65.6, 44.7 and 42.9, 36.7 and 35.7. 
νmax(ATR) 3281, 1692, 1586, 1409, 1317. HRMS (EI): calculated 
for C14H13NO3 243.0895; found 243.0897. 
4.8. Docking studies. 
The selected ligands were first submitted to a Monte Carlo 
conformational search with the MMFF94 force field in vacuo 
with Spartan ’08.50 The obtained conformers were used for 
docking studies. The structure of OYE2 was obtained by 
homology modelling on the known crystal structure of OYE1 as 
obtained from the PDB database (1OYB.pdb) with the software 
YASARA.51 The cofactor FMN was further converted to its 
reduced form FMNH2. The obtained conformers were used for 
docking studies. Docking was performed using AutoDock5 using 
the default docking parameters supplied with AutoDock in the 
'examples' subdirectory, and point charges initially assigned 
according to the AMBER03 force field, and then damped to 
mimic the less polar Gasteiger charges used to optimize the 
AutoDock scoring function. The setup was done with the 
YASARA molecular modeling program. For each ligands 50 
Autodock LGA runs were executed. Results, were sorted by 
binding energy (more positive energies indicate stronger binding, 
and negative energies mean no binding). After clustering the 50 
runs, the resulting complex conformations were originated (they 
all differ by at least 5.0 A heavy atom RMSD). Binding energy 
are reported in kcal/mol and predicted dissociation constant in 
pM units. Contacting receptor residues are also listed. The poses 
were then viewed using PyMOL.52 
Appendix A. Supplementary data 
Supplementary data (copy of NMR and IR spectra of new 
compounds, computational details) associated with this article 
can be found at 
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